Description of Pfizer Inc's Business Segments

Pfizer Inc. is a prominent global biopharmaceutical company established in 1849. It is renowned for its commitment to enhancing health by discovering, developing, and delivering innovative medicines and vaccines. The company operates through three primary business segments—Pharmaceuticals, Consumer Healthcare, and Animal Health—each of which addresses a broad spectrum of health needs across various demographics, including human patients and animals.

Business Segments

1. Pharmaceutical Segment

The Pharmaceutical segment represents the heart of Pfizers operations and stands out as one of the leading pharmaceutical businesses in the world. Pfizer develops a wide array of vaccines and medicines across multiple therapeutic areas. Key areas of focus include:

- Cardiovascular and Metabolic Diseases: Pfizer offers essential medications for managing heart disease, hypertension, and diabetes. Notable products include:
- Lipitor (atorvastatin): One of the best-selling drugs globally, it is used to lower cholesterol levels.
- Norvasc (amlodipine): Prescribed for hypertension and angina.
- Caduet: A combination medication including Lipitor and Norvasc for patients requiring both cholesterol and blood pressure management.

- Central Nervous System Disorders: Pfizers portfolio includes treatments for various mental health conditions:
- Zoloft (sertraline): An antidepressant commonly used for anxiety, depression, and other mood disorders.
- Neurontin (gabapentin): Used to treat epilepsy and neuropathic pain.

- Arthritis and Pain Management: Key products in this area consist of:
- Celebrex (celecoxib): A pain reliever particularly effective for arthritis.

- Infectious and Respiratory Diseases: The company provides medications for a range of infections:
- Zithromax (azithromycin): A broad-spectrum antibiotic.

- Urogenital Conditions: Pfizer addresses conditions affecting the urinary and reproductive systems:
- Viagra (sildenafil): Recognized for treating erectile dysfunction.

- Cancer: Pfizers oncology portfolio includes therapies such as:
- Aromasin (exemestane): Used in treating hormone receptor-positive breast cancer.

- Endocrine Disorders: Treatments for hormonal imbalances, including:
- Genotropin (somatropin): A human growth hormone to treat growth deficiencies.

- Allergies:
- Zyrtec (cetirizine): An effective antihistamine for allergy relief.

Consumer Healthcare Segment

Pfizers Consumer Healthcare division focuses on a wide range of over-the-counter (OTC) products that enhance health and wellness. This segment includes:

- Oral Care Products: Notably includes Listerine, a leader in mouthwash formulations.
- Tobacco Dependence Solutions: Includes products like Nicorette, designed to aid smoking cessation.
- Gastrointestinal Health Products: Zantac and Rolaids, effectively treating acid-related conditions and gastrointestinal discomfort.
- Skin and Eye Care Products: Neosporin for wound care, Visine for eye irritation, and Cortizone for inflammation.
- Health and Personal Care Products: Ranges from analgesics like BenGay to sleep aids like Unisom.

Pfizer actively converts specific prescription medications into OTC products, enhancing accessibility and extending the life cycle of valuable health solutions.

Animal Health Segment

The Animal Health division of Pfizer delivers a wide range of treatments for both companion animals and livestock, making it a significant entity in the veterinary market. Key product categories include:

- Parasiticides: Such as Revolution, which is used for flea and heartworm control in pets.
- Anti-inflammatory Pain Relief: Rimadyl is a leading choice for managing osteoarthritis pain in dogs.
- Antibiotics: Products like Clavamox/Synulox, targeted for treating bacterial infections in pets.
- Vaccines: A comprehensive selection of vaccines for livestock, addressing respiratory and reproductive diseases.
- Infection Treatment: Medications such as Naxcel/Excenel RTU, which are employed to treat respiratory and other internal infections in cattle.

Conclusion

Pfizer Inc. operates a diverse range of products and services across its three major business segments, demonstrating a strong commitment to innovation in healthcare. By continually addressing the evolving needs of patients, consumers, and animals, Pfizer maintains its leadership position within the global healthcare market. Its mission to discover, develop, and deliver superior health solutions drives its ongoing research and product development efforts in a rapidly changing healthcare landscape.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of Pfizer Inc Revenues by Segments


Comirnaty	14.53 %	of total Revenue
Paxlovid	6.56 %	of total Revenue
Government and Government Sponsored Paxlovid and Comirnaty	10.38 %	of total Revenue
Other Business Activities	2 %	of total Revenue
Biopharma	97.99 %	of total Revenue
U S	60.42 %	of total Revenue
International Developed Markets	23.71 %	of total Revenue
International Emerging Markets	15.87 %	of total Revenue
Biopharma U S Commercial Division	53.19 %	of total Revenue
Biopharma International Commercial Division	36.21 %	of total Revenue
Biopharma Global Hospital and Biosimilars Division	8.59 %	of total Revenue
Pfizer CentreOne	2 %	of total Revenue
Total Alliance revenues	16.19 %	of total Revenue
Royalty	2.74 %	of total Revenue
Primary Care Biopharma	38.35 %	of total Revenue
Primary Care Eliquis Biopharma	14.99 %	of total Revenue
Primary Care Prevnar Family Biopharma	11.69 %	of total Revenue
Primary Care Nurtec ODT Vydura Biopharma	2.44 %	of total Revenue
Primary Care Comirnaty Biopharma	1.61 %	of total Revenue
Primary Care Paxlovid Biopharma	1.29 %	of total Revenue
Primary Care Abrysvo Biopharma	1.25 %	of total Revenue
Primary Care FSME-IMMUN TicoVac Biopharma	0.56 %	of total Revenue
Primary Care All other Primary Care Biopharma	4.53 %	of total Revenue
Specialty Care Biopharma	20.34 %	of total Revenue
Specialty Care Vyndaqel family Biopharma	11.09 %	of total Revenue
Specialty Care Xeljanz Biopharma	1.25 %	of total Revenue
Specialty Care Zavicefta Outside the U S and Canada Biopharma	1.04 %	of total Revenue
Specialty Care Enbrel Outside the U S and Canada Biopharma	0.95 %	of total Revenue
Specialty Care Octagam Biopharma	0.84 %	of total Revenue
Specialty Care Genotropin Biopharma	0.64 %	of total Revenue
Specialty Care Cibinqo Biopharma	0.53 %	of total Revenue
Specialty Care All other Specialty Care Biopharma	4.01 %	of total Revenue
Oncology Biopharma	26.48 %	of total Revenue
Oncology Ibrance Biopharma	6.98 %	of total Revenue
Oncology Padcev Biopharma	4.09 %	of total Revenue
Oncology Xtandi Biopharma	3.07 %	of total Revenue
Oncology Lorbrena Biopharma	2.11 %	of total Revenue
Oncology Inlyta Biopharma	1.48 %	of total Revenue
Oncology Adcetris Biopharma	1.31 %	of total Revenue
Oncology Braftovi Mektovi Biopharma	1.2 %	of total Revenue
Oncology Bosulif Biopharma	0.89 %	of total Revenue
Oncology Tukysa Biopharma	0.84 %	of total Revenue
Oncology Orgovyx Biopharma	0.75 %	of total Revenue
Oncology Elrexfio Biopharma	0.55 %	of total Revenue
Oncology Talzenna Biopharma	0.35 %	of total Revenue
Oncology Tivdak Biopharma	0.23 %	of total Revenue
Oncology All other Oncology Biopharma	2.6 %	of total Revenue
Hospital and Biosimilars Biopharma	12.83 %	of total Revenue
Hospital and Biosimilars Oncology Biosimilars Biopharma	2.83 %	of total Revenue
Hospital and Biosimilars Sulperazon Outside the U S and Canada Biopharma	1.38 %	of total Revenue
Hospital and Biosimilars Inflectra Biopharma	1.26 %	of total Revenue
Hospital and Biosimilars Zithromax Biopharma	0.78 %	of total Revenue
Hospital and Biosimilars All Other Hospital and Biosimilars Biopharma	6.59 %	of total Revenue

Q1 three months ended (Mar 29 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
Comirnaty	2,100.00	14.53 %
Paxlovid	948.00	6.56 %
Government and Government Sponsored Paxlovid and Comirnaty	1,500.00	10.38 %
Other Business Activities	289.00	2 %
Biopharma	14,161.00	97.99 %
U S	8,731.00	60.42 %
International Developed Markets	3,426.00	23.71 %
International Emerging Markets	2,293.00	15.87 %
Biopharma U S Commercial Division	7,686.00	53.19 %
Biopharma International Commercial Division	5,233.00	36.21 %
Biopharma Global Hospital and Biosimilars Division	1,242.00	8.59 %
Pfizer CentreOne	289.00	2 %
Total Alliance revenues	2,339.00	16.19 %
Royalty	396.00	2.74 %
Primary Care Biopharma	5,542.00	38.35 %
Primary Care Eliquis Biopharma	2,166.00	14.99 %
Primary Care Prevnar Family Biopharma	1,690.00	11.69 %
Primary Care Nurtec ODT Vydura Biopharma	353.00	2.44 %
Primary Care Comirnaty Biopharma	232.00	1.61 %
Primary Care Paxlovid Biopharma	186.00	1.29 %
Primary Care Abrysvo Biopharma	180.00	1.25 %
Primary Care FSME-IMMUN TicoVac Biopharma	81.00	0.56 %
Primary Care All other Primary Care Biopharma	654.00	4.53 %
Specialty Care Biopharma	2,939.00	20.34 %
Specialty Care Vyndaqel family Biopharma	1,602.00	11.09 %
Specialty Care Xeljanz Biopharma	180.00	1.25 %
Specialty Care Zavicefta Outside the U S and Canada Biopharma	150.00	1.04 %
Specialty Care Enbrel Outside the U S and Canada Biopharma	138.00	0.95 %
Specialty Care Octagam Biopharma	122.00	0.84 %
Specialty Care Genotropin Biopharma	93.00	0.64 %
Specialty Care Cibinqo Biopharma	76.00	0.53 %
Specialty Care All other Specialty Care Biopharma	579.00	4.01 %
Oncology Biopharma	3,826.00	26.48 %
Oncology Ibrance Biopharma	1,008.00	6.98 %
Oncology Padcev Biopharma	591.00	4.09 %
Oncology Xtandi Biopharma	444.00	3.07 %
Oncology Lorbrena Biopharma	305.00	2.11 %
Oncology Inlyta Biopharma	214.00	1.48 %
Oncology Adcetris Biopharma	190.00	1.31 %
Oncology Braftovi Mektovi Biopharma	174.00	1.2 %
Oncology Bosulif Biopharma	129.00	0.89 %
Oncology Tukysa Biopharma	122.00	0.84 %
Oncology Orgovyx Biopharma	109.00	0.75 %
Oncology Elrexfio Biopharma	80.00	0.55 %
Oncology Talzenna Biopharma	50.00	0.35 %
Oncology Tivdak Biopharma	33.00	0.23 %
Oncology All other Oncology Biopharma	376.00	2.6 %
Hospital and Biosimilars Biopharma	1,854.00	12.83 %
Hospital and Biosimilars Oncology Biosimilars Biopharma	409.00	2.83 %
Hospital and Biosimilars Sulperazon Outside the U S and Canada Biopharma	199.00	1.38 %
Hospital and Biosimilars Inflectra Biopharma	182.00	1.26 %
Hospital and Biosimilars Zithromax Biopharma	112.00	0.78 %
Hospital and Biosimilars All Other Hospital and Biosimilars Biopharma	953.00	6.59 %
Total	14,451.00	100 %

Q1 three months ended (Mar 29 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
Comirnaty	-	-
Paxlovid	-	-
Government and Government Sponsored Paxlovid and Comirnaty	0 %	-
Other Business Activities	5.86 %	-
Biopharma	5.36 %	-
U S	4.26 %	-
International Developed Markets	7.8 %	-
International Emerging Markets	6.01 %	-
Biopharma U S Commercial Division	1.51 %	-
Biopharma International Commercial Division	7.92 %	-
Biopharma Global Hospital and Biosimilars Division	21.76 %	-
Pfizer CentreOne	5.86 %	-
Total Alliance revenues	10.7 %	-
Royalty	28.57 %	-
Primary Care Biopharma	-2.64 %	-
Primary Care Eliquis Biopharma	12.64 %	-
Primary Care Prevnar Family Biopharma	1.81 %	-
Primary Care Nurtec ODT Vydura Biopharma	42.34 %	-
Primary Care Comirnaty Biopharma	-58.94 %	-
Primary Care Paxlovid Biopharma	-62.12 %	-
Primary Care Abrysvo Biopharma	37.4 %	-
Primary Care FSME-IMMUN TicoVac Biopharma	28.57 %	-
Primary Care All other Primary Care Biopharma	7.39 %	-
Specialty Care Biopharma	12.35 %	-
Specialty Care Vyndaqel family Biopharma	7.81 %	-
Specialty Care Xeljanz Biopharma	40.63 %	-
Specialty Care Zavicefta Outside the U S and Canada Biopharma	11.11 %	-
Specialty Care Enbrel Outside the U S and Canada Biopharma	-1.43 %	-
Specialty Care Octagam Biopharma	38.64 %	-
Specialty Care Genotropin Biopharma	-2.11 %	-
Specialty Care Cibinqo Biopharma	31.03 %	-
Specialty Care All other Specialty Care Biopharma	19.14 %	-
Oncology Biopharma	9.5 %	-
Oncology Ibrance Biopharma	3.17 %	-
Oncology Padcev Biopharma	38.73 %	-
Oncology Xtandi Biopharma	-3.06 %	-
Oncology Lorbrena Biopharma	37.39 %	-
Oncology Inlyta Biopharma	-2.28 %	-
Oncology Adcetris Biopharma	-12.84 %	-
Oncology Braftovi Mektovi Biopharma	27.94 %	-
Oncology Bosulif Biopharma	-14.57 %	-
Oncology Tukysa Biopharma	19.61 %	-
Oncology Orgovyx Biopharma	43.42 %	-
Oncology Elrexfio Biopharma	33.33 %	-
Oncology Talzenna Biopharma	25 %	-
Oncology Tivdak Biopharma	0 %	-
Oncology All other Oncology Biopharma	-0.27 %	-
Hospital and Biosimilars Biopharma	13.12 %	-
Hospital and Biosimilars Oncology Biosimilars Biopharma	54.92 %	-
Hospital and Biosimilars Sulperazon Outside the U S and Canada Biopharma	21.34 %	-
Hospital and Biosimilars Inflectra Biopharma	18.95 %	-
Hospital and Biosimilars Zithromax Biopharma	-29.11 %	-
Hospital and Biosimilars All Other Hospital and Biosimilars Biopharma	5.77 %	-
Total	5.37 %	-

Q1 three months ended (Mar 29 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
Total	2,696.00	18.66 %

Q1 three months ended (Mar 29 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
Total	-9.32 %	-

Annual Report on Pfizer Inc Divisions, Sales by Country


Biopharma	97.79 %	of total Revenue
Biopharma U S Commercial Division	58.66 %	of total Revenue
Biopharma International Commercial Division	39.14 %	of total Revenue
Pfizer CentreOne	2.14 %	of total Revenue
Total Alliance revenues	14.81 %	of total Revenue
Royalty	2.64 %	of total Revenue
Primary Care Biopharma	42.86 %	of total Revenue
Primary Care Eliquis Biopharma	12.72 %	of total Revenue
Primary Care Prevnar Family Biopharma	10.38 %	of total Revenue
Primary Care Nurtec ODT Vydura Biopharma	2.28 %	of total Revenue
Primary Care Comirnaty Biopharma	6.98 %	of total Revenue
Primary Care Paxlovid Biopharma	3.77 %	of total Revenue
Primary Care Abrysvo Biopharma	1.65 %	of total Revenue
Primary Care FSME-IMMUN TicoVac Biopharma	0.51 %	of total Revenue
Primary Care All other Primary Care Biopharma	4.57 %	of total Revenue
Specialty Care Biopharma	28.04 %	of total Revenue
Specialty Care Xeljanz Biopharma	1.74 %	of total Revenue
Specialty Care Zavicefta Outside the U S and Canada Biopharma	1.02 %	of total Revenue
Specialty Care Enbrel Outside the U S and Canada Biopharma	1 %	of total Revenue
Specialty Care Octagam Biopharma	0.67 %	of total Revenue
Specialty Care Genotropin Biopharma	0.71 %	of total Revenue
Specialty Care Cibinqo Biopharma	0.45 %	of total Revenue
Specialty Care All other Specialty Care Biopharma	2.54 %	of total Revenue
Oncology Biopharma	26.9 %	of total Revenue
Oncology Ibrance Biopharma	6.59 %	of total Revenue
Oncology Padcev Biopharma	3.1 %	of total Revenue
Oncology Xtandi Biopharma	3.51 %	of total Revenue
Oncology Lorbrena Biopharma	1.63 %	of total Revenue
Oncology Inlyta Biopharma	1.47 %	of total Revenue
Oncology Adcetris Biopharma	1.45 %	of total Revenue
Oncology Braftovi Mektovi Biopharma	1.14 %	of total Revenue
Oncology Bosulif Biopharma	0.98 %	of total Revenue
Oncology Tukysa Biopharma	0.74 %	of total Revenue
Oncology Orgovyx Biopharma	0.67 %	of total Revenue
Oncology Elrexfio Biopharma	0.49 %	of total Revenue
Oncology Talzenna Biopharma	0.29 %	of total Revenue
Oncology Tivdak Biopharma	0.23 %	of total Revenue
Oncology All other Oncology Biopharma	1.8 %	of total Revenue
Pfizer Ignite	0.07 %	of total Revenue
Specialty Care Zithromax Biopharma	0.64 %	of total Revenue
Specialty Care Inflectra Biopharma	1.03 %	of total Revenue
Specialty Care All other Hospital Biopharma	6.44 %	of total Revenue
Oncology Oncology Biosimilars Biopharma	2.08 %	of total Revenue
Oncology Aromasin Biopharma	0.72 %	of total Revenue
Biopharma Primary Care	42.86 %	of total Revenue
Biopharma Comirnaty Primary Care	6.98 %	of total Revenue
Biopharma Paxlovid Primary Care	3.77 %	of total Revenue
Biopharma Excluding Comirnaty and Paxlovid Primary Care	87.04 %	of total Revenue
United States	59.25 %	of total Revenue
Developed Markets	25.87 %	of total Revenue
Emerging Markets	14.88 %	of total Revenue
Specialty Care Vyndaqel Family Biopharma	10.2 %	of total Revenue
Specialty Care Sulperazon Outside the U S and Canada Biopharma	1.04 %	of total Revenue
Specialty Care Cresemba Biopharma	0.56 %	of total Revenue

Twelve months ended 2025
PFE s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Biopharma	61,199.00	97.79 %
Biopharma U S Commercial Division	36,708.00	58.66 %
Biopharma International Commercial Division	24,491.00	39.14 %
Pfizer CentreOne	1,338.00	2.14 %
Total Alliance revenues	9,266.00	14.81 %
Royalty	1,650.00	2.64 %
Primary Care Biopharma	26,820.00	42.86 %
Primary Care Eliquis Biopharma	7,961.00	12.72 %
Primary Care Prevnar Family Biopharma	6,494.00	10.38 %
Primary Care Nurtec ODT Vydura Biopharma	1,424.00	2.28 %
Primary Care Comirnaty Biopharma	4,367.00	6.98 %
Primary Care Paxlovid Biopharma	2,362.00	3.77 %
Primary Care Abrysvo Biopharma	1,033.00	1.65 %
Primary Care FSME-IMMUN TicoVac Biopharma	319.00	0.51 %
Primary Care All other Primary Care Biopharma	2,860.00	4.57 %
Specialty Care Biopharma	17,546.00	28.04 %
Specialty Care Xeljanz Biopharma	1,087.00	1.74 %
Specialty Care Zavicefta Outside the U S and Canada Biopharma	638.00	1.02 %
Specialty Care Enbrel Outside the U S and Canada Biopharma	627.00	1 %
Specialty Care Octagam Biopharma	418.00	0.67 %
Specialty Care Genotropin Biopharma	446.00	0.71 %
Specialty Care Cibinqo Biopharma	284.00	0.45 %
Specialty Care All other Specialty Care Biopharma	1,588.00	2.54 %
Oncology Biopharma	16,834.00	26.9 %
Oncology Ibrance Biopharma	4,122.00	6.59 %
Oncology Padcev Biopharma	1,940.00	3.1 %
Oncology Xtandi Biopharma	2,194.00	3.51 %
Oncology Lorbrena Biopharma	1,023.00	1.63 %
Oncology Inlyta Biopharma	923.00	1.47 %
Oncology Adcetris Biopharma	907.00	1.45 %
Oncology Braftovi Mektovi Biopharma	716.00	1.14 %
Oncology Bosulif Biopharma	611.00	0.98 %
Oncology Tukysa Biopharma	463.00	0.74 %
Oncology Orgovyx Biopharma	421.00	0.67 %
Oncology Elrexfio Biopharma	304.00	0.49 %
Oncology Talzenna Biopharma	182.00	0.29 %
Oncology Tivdak Biopharma	147.00	0.23 %
Oncology All other Oncology Biopharma	1,127.00	1.8 %
Total	62,579.00	100 %
Pfizer Ignite	41.00	0.07 %
Specialty Care Zithromax Biopharma	399.00	0.64 %
Specialty Care Inflectra Biopharma	646.00	1.03 %
Specialty Care All other Hospital Biopharma	4,030.00	6.44 %
Oncology Oncology Biosimilars Biopharma	1,301.00	2.08 %
Oncology Aromasin Biopharma	450.00	0.72 %
Biopharma Primary Care	26,820.00	42.86 %
Biopharma Comirnaty Primary Care	4,367.00	6.98 %
Biopharma Paxlovid Primary Care	2,362.00	3.77 %
Biopharma Excluding Comirnaty and Paxlovid Primary Care	54,470.00	87.04 %
United States	37,078.00	59.25 %
Developed Markets	16,188.00	25.87 %
Emerging Markets	9,313.00	14.88 %
Specialty Care Vyndaqel Family Biopharma	6,380.00	10.2 %
Specialty Care Sulperazon Outside the U S and Canada Biopharma	653.00	1.04 %
Specialty Care Cresemba Biopharma	349.00	0.56 %

Twelve months ended 2025
PFE s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Total	7,812.00	12.48 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth
Biopharma	-1.92 %	-
Biopharma U S Commercial Division	-4.24 %	-
Biopharma International Commercial Division	1.76 %	-
Pfizer CentreOne	16.75 %	-
Total Alliance revenues	10.47 %	-
Royalty	15.95 %	-
Primary Care Biopharma	-11 %	-
Primary Care Eliquis Biopharma	8.08 %	-
Primary Care Prevnar Family Biopharma	1.29 %	-
Primary Care Nurtec ODT Vydura Biopharma	12.75 %	-
Primary Care Comirnaty Biopharma	-18.42 %	-
Primary Care Paxlovid Biopharma	-58.68 %	-
Primary Care Abrysvo Biopharma	36.82 %	-
Primary Care FSME-IMMUN TicoVac Biopharma	13.93 %	-
Primary Care All other Primary Care Biopharma	-4.38 %	-
Specialty Care Biopharma	5.37 %	-
Specialty Care Xeljanz Biopharma	-6.93 %	-
Specialty Care Zavicefta Outside the U S and Canada Biopharma	8.87 %	-
Specialty Care Enbrel Outside the U S and Canada Biopharma	-9.13 %	-
Specialty Care Octagam Biopharma	-17.88 %	-
Specialty Care Genotropin Biopharma	-5.11 %	-
Specialty Care Cibinqo Biopharma	32.09 %	-
Specialty Care All other Specialty Care Biopharma	6.65 %	-
Oncology Biopharma	7.83 %	-
Oncology Ibrance Biopharma	-5.61 %	-
Oncology Padcev Biopharma	22.17 %	-
Oncology Xtandi Biopharma	7.6 %	-
Oncology Lorbrena Biopharma	39.95 %	-
Oncology Inlyta Biopharma	-5.62 %	-
Oncology Adcetris Biopharma	-16.71 %	-
Oncology Braftovi Mektovi Biopharma	17.96 %	-
Oncology Bosulif Biopharma	-5.27 %	-
Oncology Tukysa Biopharma	-3.54 %	-
Oncology Orgovyx Biopharma	109.45 %	-
Oncology Elrexfio Biopharma	128.57 %	-
Oncology Talzenna Biopharma	55.56 %	-
Oncology Tivdak Biopharma	12.21 %	-
Oncology All other Oncology Biopharma	0.45 %	-
Total	-1.65 %	-3.1 %
Pfizer Ignite	-50 %	-
Specialty Care Sulperazon Biopharma	-	-
Specialty Care Zithromax Biopharma	-16.88 %	-
Specialty Care Inflectra Biopharma	26.92 %	-
Specialty Care Zavicefta Biopharma	-	-
Specialty Care All other Hospital Biopharma	-3.29 %	-
Oncology Oncology Biosimilars Biopharma	25.46 %	-
Oncology Aromasin Biopharma	29.68 %	-
Biopharma Primary Care	-11 %	-
Biopharma Comirnaty Primary Care	-18.42 %	-
Biopharma Paxlovid Primary Care	-58.68 %	-
Biopharma Excluding Comirnaty and Paxlovid Primary Care	6.12 %	-
United States	-4.17 %	-
Developed Markets	0.82 %	-
Emerging Markets	4.89 %	-
Specialty Care Vyndaqel Family Biopharma	17.04 %	-
Specialty Care Sulperazon Outside the U S and Canada Biopharma	2.51 %	-
Specialty Care Cresemba Biopharma	24.2 %	-
Biopharma Oncology Division	-	-
Primary Care Premarin Family Biopharma	-	-
Primary Care BMP2 Biopharma	-	-
Specialty Care BeneFIX Biopharma	-	-
Specialty Care Oxbryta Biopharma	-	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.